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In their recent study published in Journal of Clinical
Oncology, Brown et al1 integrated technology im-
provements and radiobiology-based normal tissue
protection research into a large, prospective, ran-
domized trial, which makes it an important contribu-
tion to the field of radiation oncology. It is a blueprint
example of translating initial biology-based hypotheses
through stepwise early-phase clinical investigations
into a complex randomized trial that yields a posi-
tive result.2-4 Nevertheless, with all this euphory, we
would like to step back a bit and highlight a few key
points that would need clarification in the context of
the trial’s results before we can really adopt hippo-
campal avoidance whole-brain radiotherapy (HA-
WBRT) in combination with memantine as a new
standard of care for patients with newly diagnosed
brain metastases as advocated by the authors.
First, we acknowledge that HA may have an impact
on neurocognition as observed initially by Gondi
et al,4 although the major effect is seen largely in
the short term, and long-term effects are basically
unknown. Only 41% of participants completed the
Hopkins Verbal Learning Test-Revised (HVLT-R) at 4
months, and median survival of patients alive was only
7.9 months. Thus, most patients will not benefit from
the treatment, and no clear conclusion on long-term
effects can bemade. Second, although the difference in
the individual parameters looks impressive, the overall
neurocognitive failure is still high in the HA-WBRT plus
memantine arm (60% at 6 months).
Third, HA as recommended by the treatment protocol
comes at a cost when looking at themaximum doses to
the brain: 133% (40 Gy) was allowed to , 2% of the
planning target volume (60 Gy biologically effective
dose, a/b 2 Gy). While considering these high doses,
we are concerned that with long-term follow-up, mi-
crovascular changes and cortical thinning may be
observed accompanied by long-term neurocognitive
impairment.5,6 Table A1 of the Data Supplement1 lists
the dose-volume analysis of the tumor volume and
organs a risk, with unspecified acceptable variation in
26.3% and 48.6%, respectively, which leaves the
maximum dose delivered to the brain and hippocampi
unclear.
Fourth, we have published a study on an automated
treatment planning method to significantly reduce
the overall brain dose compared with RTOG 0933.7
Still, we detected—even in the setting of prophylactic
cranial irradiation (PCI) and lower dose compared with
therapeutic WBRT—significantly more leukoence-
phalopathy when HA was used compared with simple,
straightforward lateral opposed fields.8
Fifth, the authors chose a nonspecific primary end
point (time to cognitive failure on any neuropsy-
chological test) to assess the efficacy of a specific
(ie, HA) intervention without providing a theoret-
ical rationale about the potential benefits on non–
hippocampal-dependent functions. Furthermore,
post hoc, the authors do not provide explanations for
the nonspecific beneficial effects and miss, as such,
the opportunity to have their findings properly
understood.
Finally, another factor of uncertainty is whether there
is a very steep dose-response curve with regard to
neurocognitive effects. Two trials of prophylactic WBRT
may shed some light on this question: the HA-PCI
trial (ClinicalTrials.gov identifier: NCT01780675) and
the NVALT11 trial. The NVALT11 trial investigated
PCI without hippocampal sparing in patients with
non–small-cell lung cancer and showed a higher
percentage of physician-rated neurocognitive impair-
ment in the PCI arm compared with the observation
arm.9 On the other hand, the multicenter randomized
phase III HA-PCI trial did not support a beneficial effect
of hippocampus-sparing PCI over PCI in patients with
small-cell lung cancer.10 The trial showed no dif-
ference in the percentage of patients who showed
a decline of the hippocampus-specific HVLT-R at 4
months. In consideration of these caveats, we
encourage waiting for long-term neurocognitive
and imaging results before we advocate HA-WBRT in
combination with memantine as standard of care in
patients with good performance.
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